Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B440 oral cancer vaccine in PD-1/PD-L1 inhibitor-resistant advanced urothelial cancer
jRCT2051220143Completed
- Sponsor
- Immunorock
- Start
- Jan 2023
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of B440 in transitional cell carcinoma (TCC), sponsored by Immunorock. Primary endpoint: Dose-limiting toxicity. Started Jan 2023; status: completed.
02
Drugs
B440
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on jRCT2051220143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051220143.